| Inclusion Criteria | Exclusion Criteria |
| Male or Female; aged 35-89; | History of seizure disorder, including febrile seizures, fainting spells or syncope of unknown cause(s); |
| Diagnosis of Parkinson’s disease (PD) confirmed by a neurologist with expertise in movement disorders; | Neurological disorder other than PD including stroke (mild-to-moderate micro vascular disease is allowed), traumatic brain injury, brain tumors, hydrocephalus; |
| Hoehn and Yahr stage 2 to 4; | Major or unstable medical illness; |
| On L-Dopa and/or Dopamine Agonist daily treatment regimen; | Pacemakers, neurostimulators, tattoos or metal foreign bodies in the head area; |
| On a stable medication regimen at least 2 weeks prior the enrollment in the study and, in the view of the treating neurologist, unlikely to require medication adjustments in the following 3 months; | Untreated depression; or Beck Depression Inventory (BDI)>22 |
| Posture, locomotion and balance deficits requiring at least 10 sessions of physical therapy. | Taking any of the following medications within the four weeks prior to the start of the study: imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, bupropion, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, or theophylline; |
| History of moderate or severe dementia, or Montreal Cognitive Assessment (MoCA) <22; | |
| Physical therapy treatment contraindications as determined by physiotherapist. |